Skip to main content
Evidence Snapshot

Dual specificity protein kinase TTK

CHEMBL3983 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:13:32Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3983
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dual specificity protein kinase TTK as ChEMBL target CHEMBL3983, mapped to UniProt P33981. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dual specificity protein kinase TTK
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3983
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P33981
Dual specificity protein kinase TTK
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Dual specificity protein kinase TTK matters

As of 2026-09-13

Dual specificity protein kinase TTK is reviewed as Dual specificity protein kinase TTK (UniProt P33981); Dual specificity protein kinase TTK shows clinical signal disease relevance led by cancer.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 11 approved drugs, 2581 compounds, and 490 assays, with lead potency reaching pChEMBL 10.3.

Disease context
cancer

Dual specificity protein kinase TTK shows clinical signal disease relevance led by cancer. 2 linked drugs keep the rationale reviewable. Linked drugs include BAY-1161909, BAY-1217389.

Start review with cancer because it currently carries clinical signal support. Linked drugs include BAY-1161909, BAY-1217389. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 2581 compounds, and 490 assays for this target. The dominant activity type is IC50. CHEMBL4249882 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL4249882 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
11 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Dual specificity protein kinase TTK matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P33981, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2581
Total Compounds
490
Total Assays
11
Approved Drugs
IC50: 2436.0, KI: 60.0, EC50: 10.0, KD: 324.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4249882
 10.3 Ki —
No preferred name
CHEMBL4877547
 10.2 Kd —
No preferred name
CHEMBL3911532
 10.1 Ki —
No preferred name
CHEMBL4245639
 10.1 Ki —
No preferred name
CHEMBL3927553
 10.0 Ki —

Approved Drugs

Structure Compound First Approval
FEDRATINIB
CHEMBL1287853
 2019
MIDOSTAURIN
CHEMBL608533
 2017
NINTEDANIB
CHEMBL502835
 2014
RUXOLITINIB
CHEMBL1789941
 2011
PAZOPANIB
CHEMBL477772
 2009
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:13:32Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3983